Development of Radiological/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIAID

Contract Value

Not provided

Codes & Classification
Solicitation Number

BAA-75N93026R00004

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN12

Additional Details
Set Aside

None

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
Documents5
The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), has issued a solicitation (Procurement Identifier: BAA-75N93026R00004) seeking proposals for the development of radiological/nuclear medical countermeasures (MCMs) and biodosimetry devices. This procurement is classified under NAICS Code 541715, which pertains to research and development in the physical, engineering, and life sciences (excluding nanotechnology and biotechnology), and carries the Product Service Code AN12. The primary objective of this solicitation is to advance the development of innovative medical countermeasures and biodosimetry devices that can be deployed in response to radiological or nuclear incidents. The scope encompasses research, development, and potential validation of technologies or products that can mitigate health risks associated with exposure to radiological or nuclear materials, as well as devices capable of accurately assessing biological dosimetry in affected populations. The intended outcome is to enhance national preparedness and response capabilities by expanding the portfolio of effective tools and treatments available for radiological/nuclear emergencies. Offerors are expected to deliver comprehensive solutions that address the technical and operational requirements outlined in the solicitation documents. Key deliverables may include prototype devices, validated assays, or therapeutic agents, along with supporting data demonstrating efficacy, safety, and usability in relevant scenarios. The solicitation also includes responses to questions from potential offerors, as well as several attachments (including Amendment #1 and Attachments #6, 7, and 8), which provide further clarification and guidance for proposal preparation. The place of performance for this contract is Bethesda, Maryland, United States. The contracting entity is the NIH NIAID, operating under the Department of Health and Human Services. The procurement is managed at the federal office level, and all communications regarding the solicitation should be directed to the designated contacts: Lisa Anglin ([email protected], 240-292-4402) and Robert Corno ([email protected], 240-669-5151). This opportunity is posted as a solicitation and is currently active, with a response deadline of May 4, 2026. Interested parties are encouraged to review the full solicitation and associated attachments available via the official SAM.gov listing (https://sam.gov/opp/d5bac18d4f6e4707ac3c2fa1d8e873ba/view) to ensure compliance with all requirements and to address any special considerations outlined in the documents. Contractors evaluating this opportunity should possess expertise in medical countermeasure development, biodosimetry, and related life sciences research. The solicitation is structured to support long-term research and development efforts, with requirements and objectives that are expected to remain consistent throughout the contract lifecycle. This procurement represents a significant opportunity for organizations capable of contributing to national health security through advanced scientific and technological innovation.